• Neogen Corporation recently reported fourth-quarter and full-year 2026 results showing revenue of US$225.3 million for the quarter and US$870.4 million for the year, alongside a much smaller net loss than the very large loss recorded a year earlier, and also confirmed new revenue guidance for fiscal 2027 while completing a long-running share repurchase program and later announcing the resignation of director Thierry Bernard on August 3, 2026.
• A key insight is that, despite slightly lower annual revenue, Neogen’s loss per share from continuing operations narrowed sharply year over year, which, together with its 2027 revenue outlook, has coincided with analysts raising earnings estimates and assigning the company a favorable ranking.
• With management’s new 2027 revenue guidance now in hand, we’ll examine how this updated outlook shapes Neogen’s existing investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.

Neogen Investment Narrative Recap

To own Neogen, you need to believe that tighter global food safety requirements and broader testing adoption can eventually translate its food and animal safety platforms into sustainable, higher quality revenue, even while the company is still unprofitable. The latest results and 2027 revenue guidance do not meaningfully change that core idea. In the near term, the key catalyst is operational progress on integration and margins, while the biggest risk remains continued end market softness and weak profitability.

The full year 2026 results and new 2027 revenue outlook of US$880 million to US$885 million are the most relevant updates here. They frame how quickly Neogen might rebuild credibility around its food safety growth story after a period of sizable losses, and they arrive alongside shrinking loss per share and higher Street earnings estimates, which together could sharpen investor focus on whether execution improvements are truly starting to come through in the reported numbers.

But against that improving loss profile, investors should be aware that Neogen is still expected to remain unprofitable and faces meaningful execution risk around...

Neogen's narrative projects $896.0 million revenue and $102.6 million earnings by 2029.

Uncover how Neogen's forecasts yield a $13.00 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Before this news, the most pessimistic analysts were assuming revenue could actually shrink about 2 percent a year and that Neogen might not reach profitability within three years, which is a far darker view than the more balanced narrative tied to current guidance and highlights just how differently you and other investors might interpret the same set of risks and catalysts.

Explore 3 other fair value estimates on Neogen - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Neogen research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free Neogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neogen's overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.